Robeco Institutional Asset Management B.V. Trims Stake in AbbVie Inc. $ABBV

Key Points

• Robeco Institutional Asset Management trimmed its stake in AbbVie by 3.4% in Q4, selling 112,895 shares and now holds 3,210,141 shares worth roughly $733.5 million (about 0.18% of AbbVie), making ABBV its 11th-largest holding (~1.0% of the fund).
• Quarterly results: AbbVie reported EPS of $2.71 and revenue of $16.62 billion (up 10% year-over-year), beating estimates, and provided FY/Q1 2026 guidance.
• Dividend update: AbbVie declared a quarterly dividend of $1.73 per share (annualized $6.92) for a yield of about 3.3%, with a payout ratio near 293%.

Robeco Institutional Asset Management B.V. lowered its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,210,141 shares of the company's stock after selling 112,895 shares during the period. AbbVie comprises about 1.0% of Robeco Institutional Asset Management B.V.'s holdings, making the stock its 11th largest holding. Robeco Institutional Asset Management B.V. owned approximately 0.18% of AbbVie worth $733,485,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Successful Portfolios LLC lifted its stake in AbbVie by 6.4% during the fourth quarter. Successful Portfolios LLC now owns 6,929 shares of the company's stock worth $1,525,000 after purchasing an additional 418 shares during the last quarter. Kellett Wealth Advisors LLC lifted its stake in AbbVie by 2.0% during the fourth quarter. Kellett Wealth Advisors LLC now owns 3,187 shares of the company's stock worth $728,000 after purchasing an additional 61 shares during the last quarter. Clear Creek Financial Management LLC lifted its stake in AbbVie by 28.2% during the fourth quarter. Clear Creek Financial Management LLC now owns 5,511 shares of the company's stock worth $1,259,000 after purchasing an additional 1,213 shares during the last quarter. Bowman & Co S.C. lifted its stake in AbbVie by 0.7% during the fourth quarter. Bowman & Co S.C. now owns 10,647 shares of the company's stock worth $2,434,000 after purchasing an additional 77 shares during the last quarter. Finally, Howard Capital Management Inc. lifted its stake in AbbVie by 5.9% during the fourth quarter. Howard Capital Management Inc. now owns 33,008 shares of the company's stock worth $7,542,000 after purchasing an additional 1,849 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $208.22 on Friday. AbbVie Inc. has a 1 year low of $168.54 and a 1 year high of $244.81. The company has a market cap of $368.16 billion, a PE ratio of 88.23, a P/E/G ratio of 0.75 and a beta of 0.38. The stock's 50-day moving average is $220.35 and its 200 day moving average is $224.01.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the business earned $2.16 EPS. The business's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie's dividend payout ratio is 293.22%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Barclays assumed coverage on AbbVie in a research note on Thursday, February 19th. They issued an "overweight" rating and a $275.00 target price for the company. UBS Group lowered their target price on AbbVie from $240.00 to $230.00 and set a "neutral" rating for the company in a research note on Thursday, February 5th. Weiss Ratings reissued a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, January 21st. Finally, Berenberg Bank set a $275.00 target price on AbbVie in a research note on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $253.00.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
• Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
• Positive Sentiment: Analysts and features continue to highlight AbbVie's successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit
• Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie's guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
• Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie's guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
• Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

Insider Buying and Selling

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.